Sishir Mokkapati
About Sishir Mokkapati
Sishir Mokkapati serves as the Senior Vice President of Corporate Development at Day One Biopharmaceuticals, bringing extensive experience in corporate and business development from previous roles at Cerevel Therapeutics and Bayer.
Current Role at Day One Biopharmaceuticals
Sishir Mokkapati serves as the Senior Vice President of Corporate Development at Day One Biopharmaceuticals. He has held this position since 2022, contributing to the company's strategic initiatives in Brisbane, California. In this role, he leads corporate development efforts, focusing on enhancing the company's growth and market presence.
Previous Experience at Cerevel Therapeutics
Before joining Day One Biopharmaceuticals, Mokkapati worked at Cerevel Therapeutics, LLC as Vice President, Head of Corporate and Business Development from 2020 to 2022. During his tenure in Boston, Massachusetts, he was responsible for overseeing corporate development strategies and managing complex deal teams.
Career at Bayer
Mokkapati has extensive experience at Bayer, where he held multiple positions related to mergers and acquisitions. He served as Vice President of Mergers & Acquisitions from 2015 to 2020, first in Leverkusen, Germany, and then in the Greater New York City Area. His roles included Director of Mergers & Acquisitions from 2012 to 2015 in Hong Kong SAR and Senior Manager from 2010 to 2012 in Pittsburgh, Pennsylvania.
Educational Background
Mokkapati earned a Bachelor of Science in Finance from Indiana University - Kelley School of Business, studying from 1993 to 1997. He furthered his education by obtaining an MBA in Finance and Strategy from Carnegie Mellon University - Tepper School of Business, where he studied from 2003 to 2006.
Analytical Skills and Expertise
Mokkapati possesses strong analytical and critical thinking skills, which he applies in corporate development. His broad global experience encompasses acquisitions, divestments, licensing agreements, joint ventures, and strategic alliances, allowing him to effectively interact with senior management and board-level executives.